Literature DB >> 3484753

Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab')2 fragments from monoclonal anti-carcinoembryonic antigen antibodies.

B Delaloye, A Bischof-Delaloye, F Buchegger, V von Fliedner, J P Grob, J C Volant, J Pettavel, J P Mach.   

Abstract

This clinical study was based on experimental results obtained in nude mice grafted with human colon carcinoma, showing that injected 131I-labeled F(ab')2 and Fab fragments from high affinity anti-carcinoembryonic antigen (CEA) monoclonal antibodies (MAb) gave markedly higher ratios of tumor to normal tissue localization than intact MAb. 31 patients with known colorectal carcinoma, including 10 primary tumors, 13 local tumor recurrences, and 21 metastatic involvements, were injected with 123I-labeled F(ab')2 (n = 14) or Fab (n = 17) fragments from MAb anti-CEA. The patients were examined by emission-computerized tomography (ECT) at 6, 24, and sometimes 48 h after injection using a rotating dual head scintillation camera. All 23 primary tumors and local recurrences except one were clearly visualized on at least two sections of different tomographic planes. Interestingly, nine of these patients had almost normal circulating CEA levels, and three of the visualized tumors weighed only 3-5 g. Among 19 known metastatic tumor involvements, 14 were correctly localized by ECT. Two additional liver and several bone metastases were discovered by immunoscintigraphy. Altogether, 86% of the tumor sites were detected, 82% with F(ab')2 and 89% with Fab fragments. The contrast of the tumor images obtained with Fab fragments suggests that this improved method of immunoscintigraphy has the potential to detect early tumor recurrences and thus to increase the survival of patients. The results of this retrospective study, however, should be confirmed in a prospective study before this method can be recommended for the routine diagnosis of cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484753      PMCID: PMC423340          DOI: 10.1172/JCI112291

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  The use of paired labeling in the determination of tumor-localizing antibodies.

Authors:  D PRESSMAN; E D DAY; M BLAU
Journal:  Cancer Res       Date:  1957-10       Impact factor: 12.701

2.  In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice.

Authors:  J P Mach; S Carrel; C Merenda; B Sordat; J C Cerottini
Journal:  Nature       Date:  1974-04-19       Impact factor: 49.962

3.  Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G.

Authors:  D M Goldenberg; D F Preston; F J Primus; H J Hansen
Journal:  Cancer Res       Date:  1974-01       Impact factor: 12.701

4.  Diagnostic imaging of malignant melanoma with radiolabeled antitumor antibodies.

Authors:  S M Larson; J A Carrasquillo; K A Krohn; R W McGuffin; D L Williams; I Hellström; D Lyster
Journal:  JAMA       Date:  1983-02-11       Impact factor: 56.272

5.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning.

Authors:  D M Goldenberg; F DeLand; E Kim; S Bennett; F J Primus; J R van Nagell; N Estes; P DeSimone; P Rayburn
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

6.  Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen.

Authors:  C Berche; J P Mach; J D Lumbroso; C Langlais; F Aubry; F Buchegger; S Carrel; P Rougier; C Parmentier; M Tubiana
Journal:  Br Med J (Clin Res Ed)       Date:  1982-11-20

7.  Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy.

Authors:  S M Larson
Journal:  J Nucl Med       Date:  1985-05       Impact factor: 10.057

8.  Radioimmunodetection of melanoma utilizing In-111 96.5 monoclonal antibody: a preliminary report.

Authors:  S E Halpern; R O Dillman; K F Witztum; J F Shega; P L Hagan; W M Burrows; J B Dillman; M L Clutter; R E Sobol; J M Frincke
Journal:  Radiology       Date:  1985-05       Impact factor: 11.105

9.  Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5.

Authors:  J L Murray; M G Rosenblum; R E Sobol; R M Bartholomew; C E Plager; T P Haynie; M F Jahns; H J Glenn; L Lamki; R S Benjamin
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

10.  Seizure control following administration of anticonvulsant drugs in the quaking mouse.

Authors:  S M Taylor; G D Bennett; L C Abbott; R H Finnell
Journal:  Eur J Pharmacol       Date:  1985-11-26       Impact factor: 4.432

View more
  29 in total

Review 1.  New diagnostic imaging in rectal cancer: endosonography and immunoscintigraphy.

Authors:  G Feifel; U Hildebrandt
Journal:  World J Surg       Date:  1992 Sep-Oct       Impact factor: 3.352

Review 2.  Monoclonal antibodies. Future potential in cancer chemotherapy.

Authors:  C Kosmas; H Kalofonos; A A Epenetos
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 3.  Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures".

Authors:  S H de Bie; T C Ferreira; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

4.  Carbohydrate-derivatized immunoconjugate of the anti-(carcinoembryonic antigen) monoclonal antibody C46: immunohistological reactivity and pharmacokinetic comparison with a randomly derivatized C46 immunoconjugate.

Authors:  M J Rosenstraus; W L Davis; A D Lopes; C J D'Aleo; S C Gilman
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 5.  Introduction to monoclonal antibodies.

Authors:  Jean-Pierre Mach
Journal:  Cancer Immun       Date:  2012-05-01

6.  Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2.

Authors:  M Better; S L Bernhard; S P Lei; D M Fishwild; J A Lane; S F Carroll; A H Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

7.  In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive Cancers.

Authors:  Karen J Wong; Kwamena E Baidoo; Tapan K Nayak; Kayhan Garmestani; Martin W Brechbiel; Diane E Milenic
Journal:  EJNMMI Res       Date:  2011-06-07       Impact factor: 3.138

8.  Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts.

Authors:  C Larbouret; B Robert; C Bascoul-Mollevi; F Penault-Llorca; A Ho-Pun-Cheung; S Morisseau; I Navarro-Teulon; J-P Mach; A Pèlegrin; D Azria
Journal:  Ann Oncol       Date:  2009-11-04       Impact factor: 32.976

9.  Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.

Authors:  F Buchegger; C Pfister; K Fournier; F Prevel; M Schreyer; S Carrel; J P Mach
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

Review 10.  Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?

Authors:  A B Delaloye; B Delaloye
Journal:  Eur J Nucl Med       Date:  1995-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.